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The family of 14-3-3 proteins has emerged as critical regulators of
diverse cellular responses under both physiological and pathological
conditions. Here, we report an important role of 14-3-3 in tumori-
genesis through a mechanism that involves anoikis resistance. 14-3-3
is up-regulated in a number of cancer types, including lung cancer.
Through an RNAi approach using human lung adenocarcinoma-
derived A549 cells as a model system, we have found that knockdown
of a single  isoform of 14-3-3 is sufficient to restore the sensitivity of
cancer cells to anoikis and impair their anchorage-independent
growth. Enhanced anoikis appears to be mediated in part by up-
regulated BH3-only proteins, Bad and Bim, coupled with decreased
Mcl-1, resulting in the subsequent activation of Bax. This study
suggests a model in which anchorage-independent growth of lung
cancer cells requires the presence of 14-3-3. This work not only
reveals a critical role of 14-3-3 in anoikis suppression in lung cancer
cells, but also identifies and validates 14-3-3 as a potential molecular
target for anticancer therapeutic development.
molecular target  RNAi  tumorigenesis  apoptosis  BH3-only
The 14-3-3 proteins have emerged as critical regulators of diversecellular responses in eukaryotic organisms (see refs. 1–4 for
reviews). The family of mammalian 14-3-3 proteins has seven
defined isoforms: , , ,,, , and . Initially, they were described
as enzyme cofactors that affect the activity of their associated
tryptophan and tyrosine hydroxylase, protein kinase C, exoenzyme
S ADP-ribosyltransferase, AANAT, and Raf-1 (2). The interaction
of 14-3-3 with phosphorylated Raf-1 led to the discovery of 14-3-3
as the founding member of the class of phosphoserine/threonine-
binding protein modules (5–9). The availability of well character-
ized 14-3-3 recognition motifs coupled with the use of powerful
proteomics approaches has revealed an entirely new landscape in
which 14-3-3 binds a variety of signalingmolecules, controlling their
function in response to environmental signals (9–13). In addition to
protein enzymes, 14-3-3-associated client proteins include various
transmembrane and nuclear receptors, adaptor proteins, and tran-
scription factors, thus drastically expanding the functional roles of
14-3-3. Because of the primarily phosphorylation-dictated nature of
14-3-3 interactions, 14-3-3 has been tightly integrated into the
central phosphor-relay signaling network that forms the core of
vital signal transduction pathways. Through regulated interactions
with crucial signaling mediators, 14-3-3 controls diverse cellular
responses ranging from cell proliferation and differentiation to cell
cycle checkpoint control and programmed cell death.
Because of its importance in the regulation of key signal trans-
duction pathways, dysregulation of 14-3-3 has been associated with
pathological consequences. In addition to their participation in
various neurodegenerative disorders and inflammatory diseases,
isoforms of 14-3-3 proteins have been implicated in tumorigenesis
either as potential tumor suppressors or oncogenes (3, 14–16). In
particular, 14-3-3 has attracted much attention since its discovery
as a p53-regulated cell cycle inhibitor (17, 18). The  isoform plays
an important role in several critical aspects of cell growth control,
includingmitotic translational switch (17, 19). Inmany cancer types,
14-3-3 appears to be silenced by promoter methylation or de-
graded by an ubiquitin-mediated proteolytic pathway, which is
consistent with its suggested role as a tumor suppressor (20–23).
Such down-regulation of  was correlated with oncogenesis. Inter-
estingly,  expression has a negative role in survival of lung cancer
and colorectal carcinoma patients (24, 25). On the other hand,
other 14-3-3 isoforms seem to play a role in cancer promotion,
although the underlying mechanisms remain to be defined. For
instance, overexpression of 14-3-3 promotes MAPK-dependent
tumor formation in nudemice (26).Overexpression of 14-3-3 leads
to cell adhesion to tenascin-C and an enhanced growth rate of
tumor cells (27). Thus, various 14-3-3 isoforms may offer different
opportunities for the development of novel anticancer therapeutics.
Targeting 14-3-3 with a general antagonist, such as R18 or
difopein, which induces a global inhibition of 14-3-3 function, has
been described (28, 29). This approach suggested an essential role
of the 14-3-3 family in cell survival and provided proof-of-concept
that inhibition of 14-3-3 may be able to sensitize cancer cells to
chemotherapeutic agents. However, it remains unknown whether
an individual 14-3-3 isoform has a dominant role in promoting
survival of cancer cells. Up-regulation of such an isoform would be
expected to provide a survival advantage to tumor cells.At the same
time, such an interdependent relationship of cancer cells on an
up-regulated 14-3-3 isoform may form the basis for oncogene
addiction (30), which may offer therapeutic opportunities for an
isoform-specific approach. To test this hypothesis, we examined the
contribution of 14-3-3 to oncogenesis through an RNAi approach
using human A549 adenocarcinoma cells as a model system.
Consistent with a previous report (31), 14-3-3 is indeed overex-
pressed in a number of lung cancer cell lines and in lung cancer
tissues of patients. A549 cells are highly tumorigenic and readily
form colonies in soft agar medium. Interestingly, knockdown (KD)
of a single  isoform of 14-3-3 is sufficient to impair the anchorage-
independent growth of A549 cells and restore their sensitivity to
anoikis. Our study demonstrates a critical role of 14-3-3 in sup-
pression of anoikis in lung cancer cells and, importantly, identifies
a novel target for anticancer therapeutic intervention.
Results
14-3-3 Is Up-Regulated in Cancer Cells. 14-3-3 proteins comprise a
family of seven highly homologous molecules in mammalian cells.
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To begin our systemic investigation of how each 14-3-3 isoform
contributes to cell growth control and tumorigenesis, we examined
the expression of 14-3-3 protein in human lung cancer cells. In
comparison to its expression in the cultured human normal bron-
chial epithelial cell line, BEAS-2B, 14-3-3 appeared to be up-
regulated in a panel of lung cancer cells including A549 and H358
adenocarcinoma,H1299 large cell carcinoma, Calu-1 squamous cell
carcinoma, and N417 variant small cell lung cancer cells as
determined by a -isoform-specific antibody (Fig. 1). This result
suggests that the  isoform of 14-3-3 is dysregulated in tumors.
In support of this notion, 14-3-3 was found by immunohisto-
chemistry staining to be up-regulated in four of six tumor tissues
compared with normal tissues from the same patient (Fig. 1).
These data raise the possibility that overexpression of 14-3-3
may contribute to tumorigenesis.
14-3-3 Is Required for Anchorage-Independent Growth of Tumor
Cells.To investigatewhether 14-3-3has a role in cell growth control
and tumorigenesis and explore the consequence of  isoform
inhibition, we used RNAi to reduce cellular  levels. Two stable
A549 cell lines were established expressing distinct shRNA that
target two different sequences in the 3 noncoding region of 14-3-3
mRNA, termed 14-3-3 KD1 and KD2. Compared with the pa-
rental A549 (PAR) and A549 harboring a control scrambled
shRNA (SCR), KD1 and KD2 showed diminished 14-3-3 protein
levels (Fig. 2A). Depletion of intracellular  showed no obvious
effect on the expression of other 14-3-3 isoforms.
Malignant transformation requires the acquisition of a number of
tumor features, including increased growth rate and anchorage-
independent growth potential (32). Using the defined cell lines, we
aimed to test whether the  isoform plays any role in the process of
tumorigenesis. Examination of growth rates revealed no significant
difference among control and  KD cells (Fig. 2B). An in vitro
indicator for tumorigenesis potential is the ability of transformed
cells to grow in an anchorage-independent environment (33). A549
cells grew readily and formed colonies in semisolidmediumwithout
adherence to a solid substratum (Fig. 2C). Similar sizes of colonies
were observed in SCR cells as in parental cells. In contrast,
shRNA-mediated KD of 14-3-3 was sufficient to impair the
anchorage-independent growth capability of A549 cells, leading to
a drastic reduction in the number and size of colonies formed in soft
agar medium (Fig. 2 C and D). These results revealed a novel
function of 14-3-3 in supporting anchorage-independent growth of
tumor cells. This effect is not limited to A549 cells as KD of 14-3-3
inH1299 lung cancer cells also led to a reduction in colonies formed
in the soft agar medium [supporting information (SI) Fig. 8].
Anchorage independence is an important feature that allows tumor
cells to survive under certain inappropriate host conditions, such as
during invasion and metastasis. Up-regulation of 14-3-3 may be
one of the oncogenic events that leads to anchorage-independent
survival and growth of lung cancer cells.
KD of 14-3-3 Impairs Anoikis Avoidance of Cancer Cells.Detachment
of normal epithelial cells from their substratum leads to apoptotic
cell death, termed anoikis. The anchorage-independent growth of
A549 cells reflects their enhanced ability to resist anoikis (34, 35).
It is possible that up-regulated 14-3-3 provides a molecular mech-
anism that protects A549 cells from undergoing anoikis, leading to
anchorage independence. To test this hypothesis, we compared the
apoptotic tendency of A549 cells with that of 14-3-3KD cells upon
detachment from the platematrix. ADNAcontent-based apoptosis
assaywas performedby using a fluorescence-activated cell analyzer.
Cells with subdiploid DNA content were scored as apoptotic. As a
control, a basal level of apoptosis was detected when cells were
attached to culture plates (Fig. 3). No difference in apoptosis was
Fig. 1. Expression of 14-3-3 isoform. (A) 14-3-3 expression in lung cancer
cell lines. Cell lysates (10 g) were prepared from lung cancer or control
BEAS-2B cells grown in DMEM with serum and separated by SDS/PAGE (12.5%)
(47). 14-3-3 was revealed by Western blotting with a -specific antibody
(Santa Cruz). (B) Summary of 14-3-3 expression from three experiments. The
expression levels of 14-3-3 and -actin were determined as in A and quanti-
fied by densitometry. Ratios of 14-3-3 over -actin are expressed. (C) Expres-
sion of 14-3-3 in a tissue slide is shown. Immunohistochemistry was per-
formed on a slide with paired fixed tissue samples (ABXIS) using anti-14-3-3
antibody (Immuno-Biological Lab). (Upper) Tissue slices from nonsmall cell
lung cancer patients (P1–P6). (Lower) Normal matching tissues from the same
patient. (Magnification: 10.)
Fig. 2. 14-3-3 is required for anchorage-independent growth of A549 cells.
(A) Expression of 14-3-3 isoforms in A549 parental (PAR) and scrambled (SCR)
cells and A549/14-3-3 shRNA cells (KD1 and KD2). A549 and its derivative cell
lines were grown in the presence of serum and lysed for Western blot analysis.
Expression of 14-3-3 isoforms was determined by various antibodies (, , , ,
pan from Santa Cruz; ,  from Immuno-Biological Lab;  from GeneTex; and
 from Upstate). (B) Growth curves of A549 and its derivatives in medium with
serum. (C) Colony formation of A549 and its derivative cell lines in semisolid
medium. Cells on soft agar plates were grown for 3 weeks before colonies
were stained and visualized microscopically. A representative view of each cell
line is shown. (D) Quantification of colony formation data derived from C.
Colonies were counted in a blinded fashion. Those with a diameter of50m
are defined as large and those 50 m as small colonies. Results from one
representative experiment are shown.
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observed in A549 cells either with or without 14-3-3 within the
time frame tested (Fig. 3). Upon detachment from the plate matrix,
PAR and SCR cells showed a slightly increased apoptotic activity,
suggesting that A549 lung cancer cells are relatively resistant to
anoikis. This finding is consistent with a previous report (34). On
the other hand, this anoikis resistance of A549 cells was dramati-
cally decreased by silencing of 14-3-3, showing an increased
population of apoptotic cells upon detachment from the matrix
(Fig. 3). These data strongly support a role of up-regulated 14-3-3
in protecting cancer cells from anoikis.
Because caspases are critical intermediates in anoikis pathways,
caspase activities were used to validate the 14-3-3 KD effect.
Executioner caspase activities were monitored by their cleavage of
polyADP ribose polymerase (PARP) and caspase processing. Al-
though cells attached to the plate matrix showed certain levels of
PARP cleavage upon serumwithdrawal, cells with depleted 14-3-3
showed almost complete PARP cleavage when detached from the
matrix (Fig. 4A). With isoform-specific antibodies, fully processed
caspase 7 was prominently identified in  KD cells undergoing
anoikis over control cells (Fig. 4B). In the same sample, only trace
amounts of processed caspase 3 were visible. These data suggest
that 14-3-3 plays a role in anoikis resistance in part through
suppression of caspase activation. In support of this notion, addition
of a pan-caspase inhibitor, Z-VAD-FMK, or a relatively selective
inhibitor of executioner caspase 3/7, Z-DEVD-FMK, abolished the
 effect, showing decreased DNA fragmentation regardless of the
14-3-3 background (Fig. 4C). Together, these results demonstrate a
critical role of 14-3-3 in suppression of caspase-dependent anoikis
in A549 cells.
14-3-3 Is Involved in the Biphasic Regulation of Akt. To understand
how 14-3-3 deficiency affects survival signaling of lung cancer cells,
we examined whether the status of the  isoform could alter protein
kinase Src, Pyk2, and Akt/PKB activity. Src and Pyk2 are known to
mediate antianoikis signaling in A549 cells (34). However, silencing
of 14-3-3 had no effect on Src and Pyk2 activity during anoikis (SI
Fig. 9). Akt plays a major role in cell survival by phosphorylating a
number of key proapoptotic 14-3-3 client proteins, including Bad
(36). Cellular Akt activity was assessed by the phosphorylation
status ofAkt at S473 and that of its substrate PRAS40 at T246. Cells
with 14-3-3 KD showed no difference in Akt activity from PAR
and SCR control cells under attached conditions (data not shown).
Interestingly, when A549PAR and SCR control cells were grown in
poly (2-hydroxyethyl-methacrylate) (polyHEMA)-treated culture
plates, Akt exhibited a biphasic activity. pS473-Akt decreased at
24 h and recovered at 48 h, consistent with a previous report (37).
It is possible that the recovered Akt activity represents a cellular
protective feedback mechanism to prolong survival. In contrast,
14-3-3 KD cells failed to show recovery of Akt activity after its
initial decline (Fig. 5). Thus, 14-3-3 seems to be required for the
protective feedback mechanism of Akt upon prolonged cell de-
tachment from matrix. However, this -regulated Akt activity
appears to be insufficient to explain the anoikis suppression func-
tion of  as seen in Fig. 3. Failed Akt reactivation at this late stage
unlikely contributes to the initially increased anoikis response in
14-3-3-defective cells.
Dysregulation of Bcl-2 Family Proteins Is Associated with 14-3-3
Deficiency. To identify the molecular mechanism that underlies the
enhanced anoikis in 14-3-3-deficient cells, we focused on the Bcl-2
family of apoptosis regulators that integrate cellular survival and
Fig. 3. Decreased expression of 14-3-3 is correlated with increased anoikis.
A549 or its derivative cells were grown either under attached or detached (on
polyHEMA-treated plates) conditions, and total cells were collected for DNA
content analysis. (A) Representative DNA histograms of A549 cells analyzed
with a flow cytometer. A549 PAR, SCR, KD1, and KD2 cells were grown in
polyHEMA-coated plates and harvested at time 0 (Upper) and 48 h (Lower)
after detachment for analysis. (B) Effect of 14-3-3 KD on sub-G1 DNA content
of A549 cells. Data from a representative experiment are shown.
Fig. 4. Caspase activation mediates anoikis in 14-3-3KD cells. (A) Decreased
14-3-3 is correlated with increased caspase activity upon anoikis induction.
Cells were grown either in attached or detached conditions and harvested for
Western blotting with anti-PARP antibody (Inset; Cell Signaling). Ratios of
cleaved to uncleaved PARP are summarized from three independent experi-
ments. (B) Caspase 7 is activated in A549 14-3-3 KD1 and KD2 cells. Cells were
grown on polyHEMA-treated plates and harvested for Western blotting with
anti-caspase 7 and anti-caspase 3 antibodies (Cell Signaling). Lower blots show
cleaved activated caspase 7 or caspase 3. (C) Caspase inhibitors decrease the
level of anoikis. Cells in polyHEMA-coated plates were treated with Z-VAD-
FMK or Z-DEVD-FMK before harvesting for DNA content analysis.
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apoptosis signals through their action on mitochondria (38). The
prosurvival members of the Bcl-2 family, Bcl-2, Bcl-xL, and Mcl-1,
have been shown to restrain the proapoptotic activity of Bax and
Bak, which function to induce mitochondrial outer membrane
permeability and the release of apoptogenic factors. The BH3-only
proteins sense cellular stress signals and antagonize the function of
prosurvival Bcl-2 members that guard Bax and Bak. We reasoned
that 14-3-3 levels might control the status of BH3-only proteins in
A549 cells, which, in turn, determine cancer cell susceptibility to
anoikis. To test this model, we monitored the expression levels of
both broadly acting BH3-only proteins (Bid, Puma, and Bim) and
selectively acting BH3-only proteins (Bad and Noxa) (39). Among
BH3-only proteins tested, Puma, Noxa, and Bid showed no change
in their expression levels upon cell detachment regardless of 14-3-3
status (data not shown). Strikingly, levels of Bim increased with
time when cells were grown in polyHEMA-coated plates (Fig. 6A).
However, the  status of A549 cells did not show any effect on Bim
expression, with a similar trend of Bim increase upon cell detach-
ment seen in both PAR and 14-3-3 KD cells. The change in Bim
level per se seems insufficient to explain the enhanced anoikis in 
KD cells. On the other hand, the expression level of the proapo-
ptotic protein Bad was significantly increased in 14-3-3 KD1 and
KD2 cells. It is possible that Bad coordinates with Bim to enhance
anoikis in cells with decreased 14-3-3.
The BH3-only proteins control apoptosis sensitivity by engaging
prosurvivalmembers of the Bcl-2 family. Therefore, it is the relative
ratio of BH3-only over prosurvival Bcl-2 members that impacts the
outcome of stress-induced apoptosis (38). Thus, we examined the
status of prosurvival Bcl-2members in anoikis in relation to 14-3-3
status. No significant change in Bcl-2 or Bcl-xL was observed in all
four cell lines tested under anoikis conditions (Fig. 6A). In contrast,
Mcl-1 appeared to decrease with time upon cell detachment in
14-3-3 KD1 and KD2 cells versus parental control cells (Fig. 6 A
and B). Decreased Mcl-1 and increased Bad in 14-3-3 shRNA-
treated stable cell lines along with anoikis-induced Bimmay tip the
balance in A549 cells toward enhanced apoptotic potential.
The abovemodel predicts a decreased threshold for the induction
of active Bax when 14-3-3 is reduced. To test this notion, we
monitored conformational change of Bax as an indicator of its
activation (40). Upon cell detachment, conformationally changed
active Baxwas slightly increased in PARand SCR control cells (Fig.
6 C and D). On the other hand, both KD1 and KD2 cells exhibited
a drastically increased population of cells with activated Bax,
whereas total Bax levels remained the same. These data together
suggest a vital role of the  isoform of 14-3-3 in suppression of
mitochondria-mediated anoikis in cancer cells. To further define a
role of Bad and/or Bim in mediating anoikis in KD1/KD2 cells, a
siRNA approach was used to knock down Bad and Bim (Fig. 6E).
However, Bad siRNA showed no effect on anoikis. On the other
hand, down-regulation of Bim, either alone or in combination with
Bad, significantly decreased detachment-induced Bax activation in
14-3-3 KD cells. These data support the model that Bim plays an
intimate role in transmitting enhanced anoikis signaling in 14-3-
3-deficient A549 cells.
Discussion
One of the most important oncogenic properties of cancer cells is
their ability to survive and grow in the absence of anchorage to the
extracellular matrix (32, 35). Unlike normal cells in which the
anoikis program is activated after loss of adhesion to substratum,
many cancer cells develop mechanisms that lead to anoikis resis-
tance. Such breakdown of anoikis control has been shown to
contribute significantly to the malignancy of many solid tumors,
including lung cancer (35). Thus, identification of molecular events
that control anoikis in cancer cells has significant therapeutic
implications. Here, we identify a particular isoform of 14-3-3, , as
a critical suppressor of anoikis in lung cancer cells. KD of  restores
the sensitivity of A549 cancer cells to anoikis and inhibits their
anchorage-independent growth. This effect is mediated in part by
dysregulated BH3-only protein function, leading to a lowered
Fig. 5. Decreased 14-3-3 is associated with reduced Akt/PKB activity. A549
or its derivative cells were grown on polyHEMA-coated plates in medium
without serum. At the indicated times, cells were collected and lysed for
Western blotting with the antibodies indicated.
Fig. 6. Altered expression of Bcl-2 family members in 14-3-3 KD cells. (A)
A549 cells and its derivatives were serum-starved under detached conditions
and harvested for Western blot analysis of Bim and Bad, Bcl-2, Bcl-xL, and
Mcl-1. (B) Quantification of ratio of Bim to Mcl-1 from three experiments as in
A. (C) Detection of active Bax. Cells were detached from matrix and harvested
at the indicated times. Active Bax was immunoprecipitated with an active-
conformation-specific mAb (6A7) and revealed by Western blotting with an
anti-Bax polyclonal antibody. (Upper) The conformationally changed Bax.
(Lower) Total Bax in the lysate. (D) Quantification of results from C. (E) KD of
Bim abolished detachment-induced Bax activation. A549 KD2 cells were trans-
fected with siRNA for Bad, Bim, Bad/Bim, or control from Dharmacon, and
expression of Bad and Bim was revealed by Western blotting. Activated Bax at
48 h after detachment was detected as in C.
Li et al. PNAS  January 8, 2008  vol. 105  no. 1  165
CE
LL
BI
O
LO
G
Y
threshold for the activation of Bax. Our work not only reveals an
important role of 14-3-3 in the suppression of anoikis, but also
validates 14-3-3 as a potential molecular target for the develop-
ment of anticancer agents. This 14-3-3-targeted strategy is sup-
ported by recent clinical data that associate 14-3-3 expression with
advanced disease grade and poor survival outcome of lung cancer
patients (41).
Among BH3-only proteins, Bim was shown to mediate
anoikis in mammary epithelial cells (42). Our results indicate
a critical role of Bim in mediating anoikis in lung cancer cells.
Although Bad did not further increase with time upon cell
detachment, an increase in Bad basal level in 14-3-3-deficient
cells may enhance cell susceptibility to anoikis. Interestingly,
increased Bim levels upon cell detachment were associated
with decreasedMcl-1 in 14-3-3KD cells. Bim functions in part
by inhibiting Mcl-1 (39). Taken together, matrix detachment
induced a significantly up-regulated ratio of Bim over Mcl-1 in
-reduced cells, leading to an amplified Bim proapoptotic
effect (Fig. 6). Neutralization of both classes of Bcl-2/Bcl-xL
and Mcl-1 by up-regulated Bad and Bim may account for
enhanced Bax activation, resulting in a potent anoikis
response.
There are seven known isoforms in themammalian 14-3-3 family.
KD of  appears to be sufficient to give rise to a significant
phenotype, anoikis restoration, in A549 cells, suggesting a unique
function of  that other isoforms cannot replace. These results also
point to the possibility that up-regulated 14-3-3may be part of the
oncogene addiction machinery that A549 lung cancer cells rely on
for survival (30). The gained ability to resist anoikis allows cancer
cells to invade andmetastasize, which is often fatal to patients (Fig.
7). This 14-3-3 effect is not limited to A549 cells. Further shRNA
studies with H1299 lung cancer cells also show a role of 14-3-3 in
anoikis resistance, albeit with a delayed anoikis response (SI Fig. 8).
This notion offers an attractive opportunity for therapeutic devel-
opment by inhibiting 14-3-3 to sensitize lung cancers to anoikis.
Beyond lung cancer cells, KDof 14-3-3 has been shown to promote
oncogenic properties of HaCaT cells, with increased sensitivity to
UV-induced apoptosis and cell adhesion (43).
The 14-3-3 KD effect could be achieved by a general 14-3-3
antagonist, like R18 or difopein, which competitively binds to
the amphipathic groove of 14-3-3, or preferably by 14-3-3-
selective agents (28, 44). Although a global 14-3-3 inhibitor
may be able to achieve a desired effect on multiple pathways
important for selected disease processes, small-molecule in-
hibitors are preferred for this purpose given the ability to fine
tune their use. On the other hand, a 14-3-3-selective agent
may offer additional advantages such as selectivity for tumors
with 14-3-3 dependency. Developing selective 14-3-3-
targeted agents is more challenging and could involve the
disruption of 14-3-3–specific protein–protein interactions or
-regulated pathways. Alternatively, dissection of transcription
mechanisms that control the specific expression of the 
isoform may offer additional opportunities for -specific in-
hibition. Because 14-3-3 is up-regulated in many other can-
cers, such as oral and stomach cancers (45, 46), development
of small-molecule inhibitors of 14-3-3 may find broad ther-
apeutic applications.
Materials and Methods
Cell Culture and Growth Conditions. Attached cells were grown in monolayer
culture in RPMI medium 1640 with or without FBS (10%). Detached cells were
grown in six-well plates precoated with polyHEMA (1.2%). Cells were cultured at
37°C in a humidified incubator with CO2 (5%) and air (95%).
Immunological Analysis. Cell lysate preparation and Western blotting with en-
hanced chemiluminescence system were performed essentially as described (28).
Generation of 14-3-3 KD Cell Lines. Recombinant retroviruses carrying 14-3-
3-KD shRNA were prepared with pSilencer 5.1 (Ambion). Two distinct sequences
for 14-3-3 were selected: ACGGTTCACATTCCATTAT and ATAGTTAACAGG-
GAAATAA. To generate 14-3-3-silenced stable cell lines, infected cells were
selected in the presence of puromycin (1.25 g/ml). Drug-resistant clones
were collected, pooled, and expanded. The 14-3-3 level was verified for each
experiment.
Soft Agar Colony Formation Assay. Cells (1  103) were resuspended in RPMI
medium 1640 (1.0 ml with 20% FBS and 0.33% agar) and plated over a layer of
solidified RPMI medium 1640/20% FBS/0.66% agar (2.0 ml). Plates were incu-
bated at 37°C, and colonies were stained with crystal violet (0.005%; Sigma–
Aldrich) and scored in a blinded fashion.
Anoikis and Cell Death Assays. For anoikis assays, cells were seeded on culture
plates pretreated with polyHEMA (1.2%). For DNA content analysis, both at-
tached and detached cells were collected, fixed, stained with propidium iodide,
and analyzed by a FACScan cytometer equipped with Cell Quest software (BD
Biosciences). Apoptosis marker analysis including caspase and Bax activation was
detectedbyWesternblotting.TodetectconformationalchangeofBax,cellswere
lysed in CHAPS buffer and immunoprecipitated with anti-Bax mAb (6A7). Active
Bax was detected with polyclonal anti-Bax antibody (40).
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